TY - JOUR
T1 - Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy
AU - Tantisiriwat, Woraphot
AU - Tebas, Pablo
AU - Clifford, David B.
AU - Powderly, William G.
AU - Fichtenbaum, Carl J.
PY - 1999
Y1 - 1999
N2 - Recent reports suggest that human immunodeficiency virus (HIV)- associated progressive multifocal leukoencephalopathy (PML) may improve with highly active antiretroviral therapy (HAART). We observed three patients who developed PML while receiving HAART. All patients received HAART for 4-11 months and had low plasma levels of HIV-1 RNA before the onset of symptoms of PML. Antiretroviral therapy was changed in two patients, and their plasma HIV-1 RNA levels declined significantly. Despite this virologic response, PML did not improve in these patients. The third patient's HIV-1 RNA level became undetectable while he was receiving HAAT, and his symptoms of PML improved after the addition of interferon α. Our observations suggest that PML can develop in patients who have shown clinical response to HAART. Furthermore, PML may not improve despite an adequate virologic response to HAART. Definitive therapy is still needed for PML.
AB - Recent reports suggest that human immunodeficiency virus (HIV)- associated progressive multifocal leukoencephalopathy (PML) may improve with highly active antiretroviral therapy (HAART). We observed three patients who developed PML while receiving HAART. All patients received HAART for 4-11 months and had low plasma levels of HIV-1 RNA before the onset of symptoms of PML. Antiretroviral therapy was changed in two patients, and their plasma HIV-1 RNA levels declined significantly. Despite this virologic response, PML did not improve in these patients. The third patient's HIV-1 RNA level became undetectable while he was receiving HAAT, and his symptoms of PML improved after the addition of interferon α. Our observations suggest that PML can develop in patients who have shown clinical response to HAART. Furthermore, PML may not improve despite an adequate virologic response to HAART. Definitive therapy is still needed for PML.
UR - http://www.scopus.com/inward/record.url?scp=0032938655&partnerID=8YFLogxK
U2 - 10.1086/514762
DO - 10.1086/514762
M3 - Article
C2 - 10452651
AN - SCOPUS:0032938655
SN - 1058-4838
VL - 28
SP - 1152
EP - 1154
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
ER -